Piramal Pharma Limited has received positive regulatory news as the Gujarat Pollution Control Board (GPCB) granted interim revocation of closure directions for its Dahej manufacturing facility, allowing the company to resume operations with immediate effect.

Latest Development - Operations Resume

The GPCB, through its letter dated 13th February 2026, granted interim revocation of the closure directions that were previously issued under Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974. This development allows Piramal Pharma to restart operations at its Dahej Site immediately.

Previous Regulatory Challenges

This positive development follows a series of regulatory actions that began in early February 2026. The company had previously received closure directions from GPCB on 4th February 2026, followed by an interim environmental damage compensation notice of Rs 1 crore on 10th February 2026.

Company's Commitment to Compliance

Piramal Pharma has expressed its commitment to working with GPCB to ensure that the interim directions are made final in due course. The company continues to engage with regulatory authorities to address environmental compliance matters at the facility.

Regulatory Disclosure Framework

The company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, communicating the development to both BSE Limited and the National Stock Exchange of India Limited. The disclosure was signed by Company Secretary Tanya Sanish on 14th February 2026.

Piramal Pharma Limited's overseas subsidiary, Piramal Critical Care Inc., has entered into a strategic collaboration with Blue-Zone Technologies Ltd. to develop comprehensive technology for capturing and recycling waste anaesthetic gases. The partnership aims to address environmental concerns while ensuring continued availability of essential anaesthetic products for medical procedures worldwide.

Strategic Partnership Overview

The collaboration combines Blue-Zone's innovative waste anaesthesia gas capture technology with Piramal's established global manufacturing and marketing infrastructure. This partnership specifically targets the environmental impact of volatile anaesthetics while maintaining their critical role in healthcare delivery.

Implementation Strategy

Pending regulatory approval in Europe, Blue-Zone will offer its Phoenix Deltasorb® waste anaesthetic gas capture systems to PCC's customers in France and Germany initially. Under the agreement, Blue-Zone will handle all activities related to the supply and deployment of its systems in healthcare facilities, while PCC will process the captured waste anaesthetic gas using Blue-Zone's technology to produce Sevoflurane USP for human use in Canada.

Leadership Perspective

Jeff Hampton, President and COO of Piramal Critical Care, emphasized the partnership's significance in balancing clinical needs with environmental responsibility. He stated that the collaboration enables hospitals to select inhaled anaesthetics based on clinical requirements while supporting sustainable healthcare objectives. Hampton highlighted Piramal's commitment to ensuring patients receive critical care while advancing environmentally responsible anaesthesia approaches.

Company Profiles

Piramal Critical Care operates as a global leader in anaesthesia, pain management and intrathecal therapy, serving hospitals in more than 100 countries worldwide. The company maintains manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India, all operating under strict GMP regulations with global regulatory accreditations.

Blue-Zone Technologies, based in Ontario, Canada, specializes in cleantech pharma solutions focused on waste anaesthetic gas capture, recovery, and processing. The company develops and markets equipment and processes for the complete lifecycle of volatile anaesthetics, supporting both environmental protection and anaesthetic drug production.

Future Expansion Plans

Both companies anticipate expanding the scope of waste anaesthetic gas capture, collection and recycling operations, along with the marketing of Sevoflurane USP produced from waste anaesthetic gas, into additional geographic markets beyond the initial European launch.